Results 221 to 230 of about 48,720 (296)

Beyond Delirium: Sporadic Creutzfeldt-Jakob Disease Revealed by Progressive Neurological Decline After Diabetic Ketoacidosis. [PDF]

Cureus
Abdul Rehman F, Zeeshan M, Siddique MU, Khaan K.   +3 more
europepmc   +1 more source

Influenza Vaccination Among Individuals With Type 1 Diabetes in Denmark: Coverage, Persistence, and Determinants, 2015–2022

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7923-7930, September 2026.
ABSTRACT Aims To investigate influenza vaccination coverage (IVC) and persistence with annual influenza vaccination among individuals with type 1 diabetes in Denmark and to identify clinical, demographic, and socioeconomic factors associated with vaccination status.
Vithiya Karunakaran, Ida Borreby Pedersen, Astrid Hjelholt, Mads Kjølby, Esben Thyssen Vestergaard, Ole Frøbert, Anders Aasted Isaksen, Kurt Kristensen   +7 more
wiley   +1 more source

Case Report: Case analysis of a juvenile type 1 diabetes mellitus patient with Mauriac syndrome. [PDF]

Front Endocrinol (Lausanne)
Fu R, Yang M, Guo Y, Huang Y, Li X, Zhang M.   +5 more
europepmc   +1 more source

Severity and Clinical Outcomes Among ICU Patients With Diabetic Ketoacidosis: An Analysis of the Japanese Intensive Care Patient Database. [PDF]

Crit Care Explor
Miyazaki R, Okano H, Goto S, Tanaka H, Okamoto H.   +4 more
europepmc   +1 more source

Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8560-8567, September 2026.
ABSTRACT Aims To evaluate the effect of tirzepatide on body weight, glycaemic control, insulin requirements, continuous glucose monitoring (CGM) metrics and cardiorenal parameters in adults with Type 1 diabetes (T1D) and overweight or obesity. Materials and Methods In this retrospective matched cohort study, adults with T1D, BMI ≥ 27 kg/m2, CGM use and
Amanda R. Purcell, Matilda S. G. Longfield, Natassia Rodrigo, Sarah J. Glastras   +3 more
wiley   +1 more source

Surgical abdomen masked by metabolic crisis: fulminant ischemic colitis in severe diabetic ketoacidosis - a case report and literature review. [PDF]

Front Endocrinol (Lausanne)
Chung JS, Kim JS, Ju JK.
europepmc   +1 more source

Regulatory standardisation to improve the safety of continuous glucose monitoring systems in Australia and New Zealand: joint ADS/ADEA/ADIPS/ANZSPED/NZSSD statement

Internal Medicine Journal, Volume 56, Issue 9, Page 1630-1636, September 2026.
Abstract Self‐monitoring of glycaemia is a cornerstone of diabetes management, particularly for people using insulin. Traditionally, glucose monitoring involved finger‐pricking and measuring capillary blood glucose concentration. Continuous glucose monitors (CGMs) have revolutionised self‐monitoring of glucose levels.
Sofianos Andrikopoulos, Lisa M. Raven, Ramzi Ajjan, Kate Lomax, Tara Whelan, Brett Fenton, Amanda Bartlett, Shantha Joseph, Matthew Hare, Mary B. Abraham, Hamish R. Crocket, Tom M. Wilkinson, Joanna McClintock, Benjamin J. Wheeler, Glynis P. Ross   +14 more
wiley   +1 more source

Normoglycemic High Anion Gap Metabolic Acidosis With Hyperkalemia: An Unusual Presentation of Alcoholic Ketoacidosis. [PDF]

Cureus
Mishra A, Shagil M, Singh L.
europepmc   +1 more source

A case of maturity‐onset diabetes of the young with a pathogenic HNF1A variant and a coexisting NEUROD1 variant

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1457-1466, September 2026.
ABSTRACT Aims/Introduction Maturity‐onset diabetes of the young (MODY) accounts for at least 1%–5% of diabetes cases and is usually caused by single gene variants. Accurate diagnosis of MODY is important for effective management, especially in young individuals who are lean and lack islet autoantibodies.
Tomofumi Takayoshi, Yushi Hirota, Kenji Sugawara, Aki Sugano, Mika Ohta, Takehito Takeuchi, Akane Yamamoto, Wataru Satake, Yutaka Takaoka, Wataru Ogawa   +9 more
wiley   +1 more source

Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1489-1498, September 2026.
ABSTRACT Aims/Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ‐protective effects, leading to increased use in high‐risk populations.
Takuma Koinuma, Manato Yoshida, Manabu Akazawa   +2 more
wiley   +1 more source